Eradication of HIV-1 from CNS Reservoirs: Implications for Therapeutics (R21)
Grant Amount: NIMH intends to commit approximately $1,500,000 in FY 2014 in response to this FOA and companion R01 FOA; NIDA intends to commit approximately $2,000,000 in FY2014 and companion R01 FOA; NINDS intends to commit approximately $1,500,000 in FY 2014 to fund 3-5 awards in response to this FOA and the companion R01 FOA.
This Funding Opportunity Announcement (FOA) invites research grant applications to address the problem of HIV-1 persistence focused solely on the central nervous system (CNS) of HIV-infected persons treated with Highly Active Anti-Retroviral Therapy (HAART). This FOA will support innovative research in five areas: (1) basic research to identify and characterize persistent HIV-1 in CNS derived cells such as macrophages, microglia and/or astrocytes in the setting of suppressive anti-retroviral therapy, with or without substance use; (2) basic research to determine the mechanisms involved in the temporal establishment, maintenance, and resurgence of persistent HIV-1 in CNS in relationship to the timing of antiretroviral therapy; (3) development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART, including effects of chronic substance use; (4) assessment of current and emerging eradication approaches on whether and/or how well they have successfully reactivated persistent HIV from CNS-derived cells such as macrophages, microglia and astrocytes; and (5) assessment of CNS toxicity and adverse impact of current and emerging eradication strategies. Applications ranging from basic to translational research in domestic and international settings are of interest. Multidisciplinary research teams are encouraged but not required.
National Institute on Drug Abuse US Department of Health and Human Services Public Health Service Public Health Services National Institutes of Health National Institute of Mental Health National Institute of Neurological Disorders and Stroke Division of Intramural Research
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies International Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Award Amount Notes
NIMH intends to commit approximately $1,500,000 in FY 2014 to fund 3-5 awards in response to this FOA and companion R01 FOA. Future year amounts will depend on annual appropriations.
NIDA intends to commit approximately $2,000,000 in FY2014 to fund 4-6 awards in response to this FOA and companion R01 FOA.
NINDS intends to commit approximately $1,500,000 in FY 2014 to fund 3-5 awards in response to this FOA and the companion R01 FOA.
Antiretroviral Drugs Drug Abuse HIV HIV Positive Persons Neurological Diseases or Disorders
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Companion Funding Opportunity: RFA-MH-14-170, R01 Research Project Grant
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.